Harvard Bioscience Reports Significant FY2025 Loss, Refinances Debt, and Enacts Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Harvard Bioscience reported a $56.7 million net loss for FY2025, including a $48.0 million goodwill impairment. The company refinanced its debt, alleviating going concern doubts, but at a high interest rate and with significant potential dilution from warrants and a convertible loan. A 1-for-10 reverse stock split was enacted to regain Nasdaq compliance, and operational restructuring is underway for future cost savings.

check_boxKey Events

• Significant Net Loss and Goodwill Impairment

  The company reported a net loss of $56.7 million for fiscal year 2025, a substantial increase from $12.4 million in 2024, primarily due to a $48.0 million goodwill impairment charge.

• Debt Refinancing Alleviates Going Concern Doubt

  A comprehensive debt refinancing of $40.0 million in term loans was completed on December 17, 2025, resolving prior substantial doubt about the company's ability to continue as a going concern. The new debt carries a high effective interest rate of 13.7%.

• Potential Future Dilution from Financing

  The debt refinancing included the issuance of warrants to purchase 2.0 million shares at an exercise price of $0.50 per share, and a $7.5 million convertible term loan convertible into 7.5 million shares at $1.00 per share. An S-3 registration statement was filed for the resale of up to 9.5 million shares related to these instruments.

• Reverse Stock Split for Nasdaq Compliance

  Stockholders approved a 1-for-10 reverse stock split, effective March 13, 2026, to regain compliance with Nasdaq's minimum bid price requirement, following a delisting notice received in April 2025.

auto_awesomeAnalysis

Harvard Bioscience Inc. reported a substantial net loss of $56.7 million for fiscal year 2025, primarily driven by a $48.0 million goodwill impairment charge. This follows a net loss of $12.4 million in 2024, indicating a significant deterioration in financial performance. The company successfully completed a comprehensive debt refinancing on December 17, 2025, securing $40.0 million in new term loans, which alleviated prior substantial doubt about its ability to continue as a going concern. However, this new debt bears a high effective interest rate of 13.7% and includes the issuance of warrants to purchase 2.0 million shares at $0.50 per share, and a convertible term loan for $7.5 million convertible into 7.5 million shares at $1.00 per share. The company also filed an S-3 registration statement for the potential resale of up to 9.5 million shares related to these financing activities, indicating significant potential future dilution. To address Nasdaq's minimum bid price requirement, stockholders approved a 1-for-10 reverse stock split, effective March 13, 2026. Additionally, the company announced 'Project Viking,' a manufacturing consolidation plan expected to yield $3.0 million in cost savings in 2027 and $4.0 million annually thereafter, with estimated restructuring charges of $3.4 million to $4.4 million. The company also successfully remediated material weaknesses in its internal controls over financial reporting as of December 31, 2025.